Triumeq (abacavir, dolutegravir, and lamivudine) Tablets, For Oral Use
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
April 2016
ADVERSE REACTIONS
Clinical Trials Experience
Week 144 safety and efficacy data from Phase III study ING114467...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts